Stay updated on BMS-986207 in Combination with Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the BMS-986207 in Combination with Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BMS-986207 in Combination with Immunotherapy Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study completion date for the Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody in combination with Nivolumab or with Nivolumab and Ipilimumab in Advanced Solid Tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:43.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of eligibility criteria such as a person's general health condition or prior treatments.
    Difference
    15%
    Check dated 2024-05-22T21:16:59.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:43.000Z thumbnail image

Stay in the know with updates to BMS-986207 in Combination with Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BMS-986207 in Combination with Immunotherapy Clinical Trial page.